leadf
logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma. Oy - Faron to Present at H.C. Wainwright Conference

RNS Number : 4959Y
Faron Pharmaceuticals Oy
09 September 2020
 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

Faron Pharmaceuticals to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference

 

TURKU - FINLAND, September 9, 2020 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:00 a.m. ET.

 

To access a live webcast and subsequent archived recording of the presentation, please visit the "Investors" section on Faron's website at https://www.faron.com/investors 

 

ENDS

 

 

For more information please contact:

 

Stern Investor Relations, Inc.

Julie Seidel, Naina Zaman

Phone: +(1)212 362 1200

Email: [email protected] 

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: [email protected]

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAKKCBBKBKDCCK

Quick facts: Faron Pharmaceuticals Ltd

Price: 320

Market: AIM
Market Cap: £149.81 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

on 18/9/20

3 min read